Latest Breaking News On - ப்ரோக்ரெஶந் இலவசம் பிழைப்பு - Page 6 : comparemela.com

(0) Ultimovacs ASA ( Ultimovacs , ticker ULTI), announced that it is presenting a poster today on the trial design of its ongoing Phase II INITIUM clinical study evaluating nivolumab and ipilimumab in combination with the Company s proprietary universal cancer vaccine, UV1, as first line treatment in patients with metastatic malignant melanoma, at the 2021 AACR Annual Meeting, held virtually from April 9 to April 14, 2021. The poster, titled, Nivolumab and ipilimumab +/- UV1 vaccine as 1st line treatment in patients with malignant melanoma (INITIUM-trial) , details the INITIUM study, a randomized, open label study investigating the efficacy and safety of UV1 vaccination in combination with nivolumab and ipilimumab as first line treatment in histologically confirmed unresectable metastatic melanoma patients. The INITIUM study is enrolling 154 patients, randomly assigned to the experimental arm or the control arm. Patients in the experimental arm will receive 8 UV1 vaccinations over

Hans vassgProgression free survivalOverall survivalObjective response rateப்ரோக்ரெஶந் இலவசம் பிழைப்புஓவரால் பிழைப்புபுறநிலை பதில் ரேட்